Ward A S, Li D H, Luedtke R R, Emmett-Oglesby M W
Division on Substance Abuse York State Psychiatric Institute, New York, NY, USA.
Psychopharmacology (Berl). 1996 Oct;127(3):204-12.
This study investigated the influence of genetics on extent of cocaine taking in rats that were self-administering cocaine under a progressive-ratio schedule. Fischer 344, ACI and Brown Norway rats were subjects because previous genetic studies on dopamine receptor loci have indicated that these are genetically divergent strains. All subjects were assessed for acquisition and stability of cocaine self-administration under a progressive ratio schedule. Subsequently, a dose-effect curve for cocaine self-administration was determined for each strain. Fischer 344 rats maintained a higher average breaking point than did the ACI or Brown Norway strains. In addition, dopamine receptor antagonists differentially reduced the ability of cocaine to serve as a reinforcer across the three strains. The D1-selective dopamine receptor antagonist, SCH 23390, and the D2/D3-selective dopamine receptor antagonist, eticlopride were significantly more effective in reducing the self-administration of cocaine in Brown Norway rats than for the other two strains. The results of this study demonstrate that genetic differences may play an important role in determining responding under progressive-ratio schedules for cocaine, possibly due to differences in the reinforcing efficacy of cocaine.
本研究调查了基因对在累进比率程序下自行服用可卡因的大鼠的可卡因服用量的影响。选用Fischer 344、ACI和挪威棕鼠作为实验对象,因为先前关于多巴胺受体基因座的遗传学研究表明,这些是基因差异较大的品系。所有实验对象均在累进比率程序下评估可卡因自我给药的习得和稳定性。随后,为每个品系确定可卡因自我给药的剂量效应曲线。Fischer 344大鼠维持的平均断点高于ACI或挪威棕鼠品系。此外,多巴胺受体拮抗剂在这三个品系中对可卡因作为强化物的能力有不同程度的降低作用。D1选择性多巴胺受体拮抗剂SCH 23390和D2/D3选择性多巴胺受体拮抗剂依托必利在降低挪威棕鼠可卡因自我给药方面比其他两个品系更有效。本研究结果表明,基因差异可能在决定可卡因累进比率程序下的反应中起重要作用,这可能是由于可卡因强化效力的差异所致。